Speaker Biographies

Diana Abdueva’s career spans two decades of research and innovation centered on understanding the structure, behavior, and diagnostic potential of DNA inside and outside the cell. Her work reflects a deep, sustained commitment to translating the complexity of DNA biology into tools that guide therapy and improve outcomes, turning complex DNA signal into clinically actionable insight. Dr. Abdueva holds a PhD in Computational Biology from the University of Southern California, completed postdoctoral research on DNA copy number alterations in pediatric oncology at Children’s Hospital Los Angeles, and earned a BS in Physics from the Moscow Institute of Physics and Technology.

• Precision Medicine

Arushi Agarwal joined the Health Advances team in 2011 and co-leads the Precision Medicine practice. Her work focuses on supporting biopharma and diagnostic companies in the development and commercialization of precision medicine tests to inform clinical management across the patient journey. Arushi's specific areas of focus include companion diagnostics, liquid biopsy testing and digital biomarkers. Prior to joining Health Advances, Arushi received her Masters in Biomedical Engineering from Columbia University and Bachelors in Biology from the Massachusetts Institute of Technology.

• Precision Medicine

Lisa Alderson is the CEO of Adela, Inc. Lisa is a mission-driven entrepreneur dedicated to improving patient care and advancing the adoption of precision medicine. She has extensive experience creating and scaling innovative, high-growth businesses at the intersection of technology and healthcare with a focus in genomics, digital health, SaaS, telehealth and molecular diagnostics. Previously, she co-founded and served as the CEO of Genome Medical, the leading genomic care delivery company enabling broad-based access to genomic medicine. She is also a co-founder of Clarified Precision Medicine. Prior, Ms. Alderson served as the Chief Commercial Officer and Chief Strategy Officer of Invitae (acquired by Labcorp), a genetic information company, and was part of the start-up team at Genomic Health Inc. (acquired by Exact Sciences). She was previously president and CEO of Crossloop, (acquired by Nasdaq: AVG), president of Cinema Circle Inc., (acquired by Nasdaq: GAIA) and the former manager of strategic planning at The Walt Disney Co. She has an MBA with distinction from Harvard Business School and a BA from Colorado State University, where she graduated Summa Cum Laude.

• Artificial Intelligence
• Diagnostics Innovation
• Precision Medicine

Recognized by Business Insider in 2025 as “one of the top 100 early-stage investors,” Dr. Alucozai has experience translating exceptional science and technology into scalable commercial ventures. Alongside his experience as a founder and operator, he has actively invested in over 100 startups across North America and Europe. He has often been the first investor to back high-growth companies like Seqera Labs. Milad began his career as a neuroscientist at the intersection of bioengineering, computational biology, and machine learning, where he commercialized platforms designed to deliver promising medicines to patients more efficiently and safely. His focus as an investor has been to accelerate the journey of groundbreaking discoveries from the lab to the market, particularly in the life sciences sector and related computational fields. Milad is a co-founder and General Partner at Pamir Ventures, an early-stage venture firm that invests in technical pioneers developing B2B companies utilizing AI in antiquated industries. He is also a co-founder of Revalia Bio, which aims to establish a human-centric infrastructure for drug discovery and development. By using non-transplantable human organs donated for research, Revalia offers the scientific community unparalleled insights into patient biology, ultimately aiding in the creation of improved treatments and cures. Throughout his operating and investing career, Milad has played a crucial role in helping founders secure hundreds of millions in capital and facilitating over $1 billion in startup-pharma partnerships. His previous roles include supporting business development at Accenture, Absci, Bit Bio, Numerate, Mekonos, and AstraZeneca. Through Digitalis Commons, he was an Expert in Residence in support of the Advanced Research Projects Agency for Health (ARPA-H), where he aided the US government and ARPA-H mission to enable transformative biomedical and health breakthroughs, providing health solutions through $1.5 billion in non-dilutive investments. He was a National Science Foundation Scholar and Macklin Fellow at Johns Hopkins Medicine. He graduated Phi Beta Kappa with a degree in Neuroscience from Purdue University’s Honors Program, earned a master’s in Immunology and Public Health as a George J. Mitchell Scholar, and holds a doctorate from the Richard M. Fairbanks School of Public Health. Additionally, he completed a Visiting Scholar appointment at the Wyss Institute at Harvard University.

• Artificial Intelligence
• Diagnostics Innovation
• Precision Medicine

Alex Aravanis is CEO and co-founder of Moonwalk Biosciences, Inc. Prior to Moonwalk, Alex was Illumina’s Chief Technology Officer, Head of Research and Product Development where he was responsible for leading Illumina’s research and product development programs. Under his leadership, Illumina launched the industry’s leading products for genomics-based research and clinical applications, including whole genome sequencing, comprehensive genomic profiling of cancer, COVID-Seq, and the most advanced AI tools for interpreting genomic information. Alex is an experienced entrepreneur and was involved in founding several start-ups in life sciences and healthcare. Most recently, he co-founded GRAIL Bio where he served as Chief Scientific Officer and Head of R&D. At GRAIL, Aravanis led the research, development, operational, and clinical teams developing its multi-cancer early detection test. Prior to GRAIL, Alex served as Senior Director of R&D for Illumina, Inc., where he developed multiple technologies, including clinical assays for the analysis of RNA and DNA from fixed tissues, whole exome analysis, massively parallel single cell transcriptomics, and liquid biopsy using cell-free nucleic acids. Alex earned a BS in Electrical Engineering, Computer Science, and Physics Minor from the University of California, Berkeley, as well as an MS and PhD in Electrical Engineering, and an MD from Stanford University. He holds more than 30 (pending and issued) patents and numerous peer-reviewed publications, additionally he serves on various Scientific Advisory Boards for biotech startups.

• Artificial Intelligence

Pierre Arsène is the Founder and Chief Executive Officer of Mursla Bio. He founded the company while conducting postgraduate research at the University of Cambridge. He is the author and inventor of several patents in the fields of nanoelectronics and extracellular vesicle characterization. Before this, he gained a decade of experience in healthcare investment banking at J.P. Morgan, where he closed over $70 billion in M&A transactions and was also appointed EMEA junior resource manager as well as the firm’s first global M&A representative in Japan. Pierre holds a Masters in Management from HEC Paris and has completed a classe préparatoire programme specializing in mathematics at Saint-Jean de Douai (equivalent to an undergraduate degree).

• Artificial Intelligence
• Precision Medicine

Mara G. Aspinall is a healthcare industry leader with a commitment to civic involvement. Aspinall is a Partner at Illumina Ventures, an independent venture capital firm focused on genomics and precision health investing in diagnostics, life science tools and therapeutics. Aspinall was President and CEO of Ventana Medical Systems, a billion-dollar division of The Roche Group, (now Roche Tissue Diagnostics), a worldwide leader in the development and commercialization of tissue-based cancer diagnostics, where she led more than two dozen major instrument and assay launches and positioned the company as a global leader in companion diagnostics. Previously, Mara was President of Genzyme Genetics and Genzyme Pharmaceuticals. She transformed Genzyme Genetics from a niche player to one of the top five laboratories in the US. The business was sold to LabCorp for ~$1 billion. She grew Genzyme Pharmaceuticals four-fold to become a leader in specialized manufacturing. Throughout her career, Aspinall has spearheaded initiatives to educate the healthcare community on genomics and diagnostics. She is Editor of the popular Sensitive & Specific: The Testing Newsletter and the annual Diagnostics Year in Review. This commitment to expanding knowledge inspired Aspinall to co-found the Biomedical Diagnostics master’s degree program at Arizona State University, the only program in the world dedicated exclusively to diagnostics, genetics and genomics. Aspinall was named Arizona Biosciences Leader of the Year by the Arizona Biotechnology Association and one of “100 Most Inspiring People in Life Sciences” by PharmaVOICE magazine. She holds an MBA from Harvard Business School, a BA from Tufts University, and is certified in Cybersecurity Oversight from Carnegie Mellon and NACD. Aspinall is a member of the Board of Directors of OraSure Technologies and Blue Cross Blue Shield of Arizona.

• Artificial Intelligence
• Diagnostics Innovation
• Precision Medicine

Dr. Esther Babady, PhD, is a board-certified clinical microbiologist with expertise in the molecular laboratory diagnosis of infectious diseases. She received her doctoral degree in Biochemistry and Molecular Biology and completed a post-doctoral fellowship in Clinical Microbiology both at the Mayo Clinic in Rochester, MN. She is currently the chief of the Clinical Microbiology Service, an Attending Microbiologist, and Professor in the Department of Pathology and Laboratory Medicine and the Department of Medicine (Infectious Disease Service) at Memorial Sloan Kettering Cancer Center. At a national level, she serves on several professional societies’ committees including those of the American Society for Microbiology, the Pan-American Society for Clinical Virology, and the Association for Molecular Pathology. Her research focus is on the rapid diagnosis of infectious diseases using molecular-based methods and the application of molecular methods for the surveillance and prevention of healthcare-acquired infections primarily in immunocompromised cancer patients. Dr. Babady has published extensively on diagnostic molecular microbiology tests. She is a Senior Editor for Microbiology Spectrum and also serves on the editorial boards of the Journal of Clinical Virology and the Journal of Molecular Diagnostics. She is an elected fellow of the Infectious Disease Society of America and the American Academy of Microbiology.

• Diagnostics Innovation

Dr. Tomasz (Tom) Beer serves as Chief Medical Officer for Multi-Cancer Early Detection at Exact Sciences Corporation since August 2022. Dr. Beer also serves as Adjunct Professor of Medicine at the OHSU Knight Cancer Institute, where he sees men with prostate cancer. Until August 2022, Dr. Beer was the Grover C. Bagby Endowed Chair for Prostate Cancer Research at the OHSU Knight Cancer Institute, where he led the Prostate Cancer Research Program, encompassing basic research, translational research, clinical trials of novel therapeutic strategies in prostate cancer, and studies aimed at enhancing cancer survivorship. He has authored or co-authored more than 280 peer reviewed articles, including investigations of targeted therapies and immunotherapies in prostate cancer, among them vitamin D receptor agonists, androgen receptor antagonists, PSMA targeted radiopharmaceuticals, clustering targeting agents as well as cancer vaccines, CTLA-4 and PD-1 inhibitors, and others. He led the global randomized trial of enzalutamide vs. placebo that demonstrated substantial improvements in overall and progression-free survival as well as quality of life and served as the basis for a global change in the standard of care for advanced prostate cancer. Dr. Beer also served as Deputy Director of the OHSU Knight Cancer institute, and NCI designated Comprehensive Cancer Center and Chief Medical Officer for the Center for Early Detection Advanced Research (CEDAR) within the Knight where he worked closely with a diverse leadership team to speed advances in the early detection of lethal cancers. At CEDAR, Dr. Beer fostered collaborations between clinicians, engineers, and cancer biologists to advance discoveries in early detection of cancer and lead clinical trials of multi-omic blood-based cancer early detection tests.

• Precision Medicine

Suzanne Belinson, PhD, MPH, is Vice President of Commercial Markets at Tempus Labs Inc. Tempus is a technology company that is making precision medicine a reality by gathering and analyzing clinical and molecular data at scale. Her role focuses on commercial growth for Tempus through the development and execution of partnerships with managed care organizations aiming to improve healthcare value by leveraging data. Before joining Tempus, Dr. Belinson served as Executive Director, Clinical Markets, at the Blue Cross Blue Shield Association. In addition to leading the sales and market development for products and services developed within the Office of Clinical Affairs, Dr. Belinson led the day to day operations of Evidence Street. As part of the leadership team in the Office of Clinical Affairs she also spent time focused on the development of emerging programs and services that enhance value and brand leadership for the independent BCBS Plans. Dr. Belinson received her bachelor’s degree from Cleveland State University, and a PhD in Epidemiology from the University of North Carolina at Chapel Hill. She also holds a Masters in Public Health from the University of Pittsburgh.

• Diagnostics Innovation

Sivan is a recognized innovator and entrepreneur in artificial intelligence who has dedicated nearly two decades to pioneering the development of complex computational and data platforms. His key contributions include the development of novel machine-learning models tackling key challenges in human disease. At Karius, he spearheaded the development of the foundational computational platform and AI strategy underlying the Karius Spectrum test, pioneered the biomarker discovery program, and was central to forming and nurturing key strategic partnerships, furthering the company’s impact in the medical field. Prior to Karius, Sivan was a co-founder and Chief Technology Officer at Lifecode, where he led the development of the analytical platform and validation of several clinical assays across oncology and rare diseases. He holds a PhD in Computer Science from the Technion - Israel Institute of Technology and continued to Stanford’s Artificial Intelligence Lab to pursue his post-doctoral research.

• Diagnostics Innovation

Paul Beresford is SVP of Biopharma Partnerships at PathAI, where he drives biopharma partnering to advance AI-powered pathology in drug discovery, clinical trials, and companion diagnostics. He has over 20 years of leadership experience across diagnostics and precision medicine, with senior roles at Danaher, Agilent Technologies, Biodesix, and Ventana (Roche Diagnostics). Paul completed his postdoctoral training and served as junior faculty at Harvard Medical School after earning his PhD in Immunology from Tufts University.

• Artificial Intelligence

Doug Biehn is an accomplished leader with over 20 years of healthcare experience building and scaling growth businesses, leading and inspiring world class teams and establishing innovative new standards of care. Prior to joining Octave, Doug held executive leadership roles in such category creating and industry leading companies as iRhythm Technologies, McKesson, AliveCor, Blue Shield of California and most recently, Cala Health. Additionally, he is a Board Advisor for a number of early-stage digital health companies and mentors graduate students in the Stanford Business School Lean Launchpad program. Doug holds an MBA from the University of San Francisco and a BS from San Francisco State University.

• Precision Medicine

I lead health initiatives in translational medicine and oncology, clinical trial infrastructure, biomarker development, and biomedical data tool generation. I am the Director of the Cancer Systems Biology Center at the City of Hope Comprehensive Cancer Center, where I am a Professor of Oncology and Therapeutics. I have over 20 years of experience performing cancer research and leading large, multi-site national teams responsible for developing and executing translational initiatives that span pre-clinical studies to clinical trials. I have managed program budgets over hundreds of millions of dollars with high clinical impact, and have worked with ARPA-H, a new US government institute focused on transformative research to drive biomedical health.

• Artificial Intelligence

Dean is a visionary entrepreneur with a personal mission to advance cancer care through AI and precision medicine. He has dedicated his career to harnessing artificial intelligence and multimodal data to improve diagnosis, research, and personalized care. In 2020, Dean co-founded Imagene AI, where he serves as CEO. Imagene AI develops a Cross-Modality Intelligence Engine that powers the OI Suite platform, deriving meaningful insights from histopathology, molecular, and clinical data to support biomarker discovery and drug development. The company is backed by leading investors, including Larry Ellison.

• Artificial Intelligence

No bio available.

• Artificial Intelligence

James Broughton has over 11 years of experience in RNA biology and RNA binding proteins - including CRISPR-Cas systems. At Mammoth, James leads the Assay Innovation team at Mammoth Biosciences. This team is responsible for developing new CRISPR-based diagnostic technologies. The scope of the team’s work includes, Cas enzyme discovery and engineering, ideation and testing of novel assay chemistries, and development of bioinformatics tool development to design diagnostic assays.

• Diagnostics Innovation

Steve Brown is the Founder and CEO of CureWise, an AI platform that helps cancer patients understand their medical and molecular data so they can work more effectively with their care teams. He began developing CureWise during his own rare cancer diagnosis, where he saw that the most precise therapies often lie beyond standard protocols and that patients only reach them when they understand their disease well enough to advocate for themselves. A veteran entrepreneur in digital health, Steve previously founded Health Hero Network, the remote-monitoring pioneer whose collaborations with the VA and CMS helped define Medicare’s telehealth reimbursement pathways. He is an inventor on more than 200 patents across AI, health monitoring, and behavioral science. Before CureWise, he produced award-winning documentaries through Ignite Channel and served as Chief AI Officer for Abundance360. He holds a degree in Physics from Stanford.

• Artificial Intelligence

No bio available.

• Artificial Intelligence

Ben Busby, PhD, is a renowned leader in biomedical informatics, computational biology, and interdisciplinary data science. With a career spanning academia, industry, and government, he is dedicated to making biomedical data science a more productive and collaborative environment for bioinformaticians and data scientists. Dr. Busby currently serves as Senior Alliances Manager, Genomics at NVIDIA, where he drives strategic collaborations and innovations in genomics, AI, and biomedical research. He is also an Adjunct Faculty Member in the Computational Biology Department at Carnegie Mellon University, contributing to cutting-edge research and education. Prior to his role at NVIDIA, Dr. Busby was a Principal Scientist at DNAnexus, where he prototyped scientific data integration solutions and built complex compute environments for users of the UK BioBank and other major biomedical research initiatives across academia, industry, and government. He also led prototype software development in machine learning, omics, imaging, pharmacogenomics, and natural language processing (NLP), often through global hackathons that he organized and participated in. Prior to DNAnexus, Ben consulted for Johns Hopkins University, Ariel Precision Medicine, Deloitte, and NCBI, as well as founding the Bioinformatics and Data Science department at the FAES Graduate School on the NIH campus.His expertise spans biomedical informatics, deep learning, interdisciplinary collaboration, AI-driven knowledge graphs, and computational biology. He holds a PhD in Biochemistry from the University of Maryland, Baltimore, and an undergraduate degree in Biochemistry from the University of Maryland, Baltimore County.

• Artificial Intelligence

No bio available.

• Precision Medicine

Justin is a Partner at Eclipse, where he collaborates with founders working at the intersection of multiple disciplines. He is particularly passionate about novel approaches to complex issues in infrastructure in healthcare and life sciences. Justin works with companies building technologies, products, and services that enable the development and, ultimately, the foundation upon which the next generation of healthcare and life sciences advancements can thrive. His focus is on building the infrastructure of these industries, closing the gap between scientific development and clinical deployment. Prior to joining Eclipse, Justin built and led the commercial operations at Misfit, a digital health company acquired by the Fossil Group for more than $250M. Before Misfit, Justin managed the commercialization efforts in the foods, fuels, and chemicals spaces at Synthetic Genomics (SGI), a leading synthetic biology company. Justin received his B.S. in Chemical Engineering from UCSB and his MBA from MIT Sloan. He sits on the Industry Alliance Board of the California Institute for Regenerative Medicine (CIRM) and the Commercial Advisory Board of the National Science Foundation Center for Cell Manufacturing Technology (CMat). Justin enjoys skiing, mountain biking, and sailing and leads the Kathryn Butler Foundation in honor of his late wife, where he is working to support the needs of those battling cancer and bereaved children.

• Artificial Intelligence

Vikram Chaudhery is a Partner at Genoa Ventures and Co-Founder & President of General Inception, with a proven track record as a life sciences investor, entrepreneur, and business leader. At Genoa, he has led investments and serves on the Board of Directors of companies like Epitel, SimBioSys, Attune Neurosciences and BrainBox Solutions, achieving six FDA clearances for AI-powered diagnostic and medical device products. His portfolio investments are driving innovations transforming patient care in oncology, neurology, and precision medicine. As Co-Founder of General Inception, Vikram has helped launch over 50 companies since 2020, with over $250M in external funding, including university spin-outs translating academic breakthroughs into market-ready solutions. General Inception specializes in bridging the gap between discovery and commercialization, particularly in AI-driven advancements in therapeutics, diagnostics, and engineered biology. Previously, Vikram headed Life Sciences at Lam Research and advised on life sciences strategy at McKinsey & Co. He holds a Ph.D. in Electrical Engineering from the University of Illinois at Urbana-Champaign.

• Artificial Intelligence

Julia Cheek is the Founder and CEO of Everlywell, a digital health company pioneering the next generation of biomarker intelligence-combining AI-powered technology with human insight to deliver personalized, actionable health answers. Over the past decade, Everlywell has delivered close to 1 billion health insights, transforming care for 60 million people and powering hundreds of enterprise partners. Julia is a visionary leader, serving on the Board of Directors for Headspace and The University of Texas at Austin President's Innovation Board. She demonstrates her passion for entrepreneurship by supporting underrepresented founders, investing in over a dozen healthcare startups. Julia was named a 2024 Digital Health Icon by Rock Health, 2023 Entrepreneur of the Year by Springboard Enterprises, and Fortune Magazine's 2022 15 Most Powerful Women in Startups. Julia attended Vanderbilt University and earned her MBA from Harvard Business School where she graduated as a Baker Scholar with high distinction. She is based in Austin, TX.

• Artificial Intelligence
• Diagnostics Innovation
• Precision Medicine

No bio available.

• Artificial Intelligence

Charles Chiu, MD, PhD is Professor of Laboratory Medicine and Medicine, Division of Infectious Diseases at University of California, San Francisco, Director of the UCSF-Abbott Viral Diagnostics and Discovery Center (VDDC), and Associate Director of the UCSF Clinical Microbiology Laboratory. Chiu currently heads a translational research laboratory focused on next-generation sequencing assay development for infectious disease diagnostics, discovery and investigation of emerging pathogens, including Borrelia burgdorferi (Lyme disease), Ebola virus, enterovirus D68, and Zika virus, and clinical/public health applications of new diagnostic technologies such as nanopore sequencing. He is also actively developing RNA sequencing approaches to detect and identify diagnostic profiles of the body’s response to infection. His work is supported by funding from the National Institutes of Health (NIH), Abbott Laboratories, Department of Defense, NASA/Translational Research Institute, philanthropic grants (Charles and Helen Schwab and Steven and Alexandra Cohen Foundations), and the California Initiative to Advance Precision Medicine. Dr. Chiu has authored more than 80 peer-reviewed publications, holds over 15 patents and patent applications, and serves on the scientific advisory boards for Therabio, Inc., and Mammoth Biosciences, Inc.

• Diagnostics Innovation

Ezra Cohen, MD joined Tempus Labs in May 2023 as the CMO, Oncology. Dr. Cohen is a leading medical oncologist and cancer researcher. Prior to Tempus he was the Chief of the Division of Hematology-Oncology as well as the Associate Director of Clinical Science at UCSD Moores Cancer Center. Dr. Cohen obtained his medical degree from University of Toronto in 1990 and trained in internal medicine at Albert Einstein College of Medicine. Subsequently, he completed a hematology/oncology fellowship at the University of Chicago and joined the faculty there in 2002. He joined the faculty at UCSD in 2014 as full professor.

• Precision Medicine

Ann is a General Partner at Engine Ventures. She serves as a Board Member for Vaxess Technologies, Droplet Biosciences, Matrisome Bio, Cellino Bio, Predicta Biosciences, and Bexorg. Before joining Engine Ventures, Ann was at Sanofi where she held senior roles in business development and strategic venture investment. Prior to Sanofi, she was at Flagship Pioneering. Ann started her career in R&D at 3M Company, working across fields of materials, biology and engineering. Ann holds an MBA from Harvard and a PhD in Chemical Engineering from MIT. She serves as a Key Advisory Board member of Harvard’s Blavatnik Fellowship in Life Science Entrepreneurship, she is a member of Investment Advisory Committee for Prime Coalition and she serves on the Board of Directors of Nucleate.

• Artificial Intelligence

Meesha Dogan is the CEO, Co-Founder, and Director of Cardio Diagnostics, where she has led the company from breakthrough innovation to national commercialization. A pioneer at the intersection of epigenetics, artificial intelligence, and cardiovascular medicine, she co-invented the company’s core technology and has led its evolution from concept to clinical impact. Under her leadership, Cardio Diagnostics has secured strategic partnerships, multiple funding rounds, and recognition, including Fast Company’s Next Big Things in Tech, and the Biotech Breakthrough Awards. Dr. Dogan, who holds a PhD in Biomedical Engineering, was recently named to the Cardiovascular Business’s 40 Under 40 and Crain's Chicago Business's 40 Under 40, and is driven by both innovation and a personal mission to change the trajectory of heart disease.

• Precision Medicine

Jim Foote is the Co-Founder and CEO of First Ascent Biomedical, a company that uses drug sensitivity testing, genomics, and AI to deliver a personalized treatment plan to cancer patients. First Ascent’s platform combines first-of-its-kind biology and technology to test 100s of FDA-approved drugs against a patient’s biopsy, prospectively determining the most effective drug/drug combinations for a patient and doctor in about 10 days. Jim has an MBA and an award-winning career in technology, solving complex problems. When his son lost his life to cancer, Jim saw firsthand how few tools and technologies doctors had available to them for something as important as cancer. Jim knew it was a solvable problem. First, Ascent Biomedical's published clinical results are at the forefront of Functional Precision Medicine (FPM), leading the transformation of cancer treatment.

• Artificial Intelligence

Ajay Gannerkote has spent over 20 years in the healthcare space spanning Life Sciences, Diagnostics and Medical Devices, and was appointed President of Integrated DNA Technologies in January 2025. Ajay joined IDT from Siemens Healthineers, where he was the President of the global ultrasound business covering both diagnostic and interventional businesses. Prior to Siemens Healthineers, Ajay served in leadership positions at KKR, McKinsey, Federal-Mogul and Infosys Technologies. At KKR, Ajay led the portfolio operations group for the Healthcare sector covering over $40B of investments across multiple sectors. Ajay specifically led transformations at Panasonic Healthcare eventually leading to a successful IPO as well as transformations at AmSurg, a large ASC network in the US. At McKinsey, as Partner, Ajay led the global medical products operations group covering devices, life sciences tools, diagnostics and pharma sectors serving clients globally in strategy, commercial, product development, manufacturing and supply chain functions. At Federal-Mogul, Ajay led plant operations and supply chain management for the sealing systems and Aftermarket businesses respectively. Ajay has an MBA from University of Michigan, Ann Arbor and a bachelor’s degree in Electronics and Communication Engineering from University of Mysore, India.

• Precision Medicine

Steve has over 30 years’ experience building world-class teams, products and companies in precision medicine, drug discovery and computational biology in the UK, EU and USA. He has developed world-leading genomics, AI enabled drug discovery, precision medicine, and complex data analytics for life science, healthcare and clinical decision support including several patented inventions. He was Global Director of Research Informatics for Astra and involved in the early Human Genome project. He has worked with multiple pharma companies on 30+ drug discovery and development projects. Steve is Chair of the UK BioIndustry Association’s Data, AI and Genomics Advisory Committee, Co-Chair of the Metrodora Foundation’s Scientific Advisory Board, Expert in Residence at Oxford University, an Editorial Board member for AI in the Life Sciences and was on the Steering Committee of the UKCRC Tissue Directory & Coordination Centre. He advises a range of disease charities, national biobanks and research institutes on precision medicine strategy.

• Precision Medicine

Mark Gardner is Senior Vice President, Molecular Genomics and Oncology for Quest Diagnostics. In this role, Mark is responsible for driving growth in Quest’s Advanced Diagnostics offerings by providing genetic sequencing services, cancer diagnostics and working closely with all our clinical franchises. Mark joined Quest in 2022 from Corza Medical, a private equity operating company focused on surgical technologies and tools, where he served as Executive Partner, Senior Vice President and General Manager of European Commercial Operations and Biosurgery Products. Prior to that, Mark served in leadership positions at a range of companies including Thermo Fisher Scientific, Life Technologies, Invitrogen and Omniseq. He started his civilian career as a consultant with the global management consulting firm McKinsey & Company, after leaving the U.S. Navy, where he was a Lieutenant Commander. Mark earned an MBA from the Wharton School at the University of Pennsylvania, a master’s degree in national security studies from Georgetown University, and a bachelor’s degree from the U.S. Naval Academy.

• Precision Medicine

No bio available.

• Artificial Intelligence

Gary Gustavsen joined Health Advances in 2005 and co-leads its Precision Medicine Practice. A noted writer and workshop leader in the field of companion diagnostics and personalized medicine, his work focuses on commercialization strategy, value justification, and due diligence for both diagnostic and therapeutic companies. Prior to joining Health Advances, Gary held research positions at Brookhaven National Lab, Becton Dickinson, OSI Pharmaceuticals, and Millennium Pharmaceuticals. Gary has a background in Biomedical Engineering with a bachelor’s degree from Duke University and a master’s degree from Stony Brook University.

• Artificial Intelligence

Noosheen Hashemi is the co-founder and CEO of January AI, a precision health company applying artificial intelligence to extend healthspan. She leads the company’s two flagship innovations: a patented virtual continuous glucose monitor that predicts blood sugar responses to food in real time, and Mirror, a Health Context Engine that organizes fragmented health data into a clinically grounded Personal Health Knowledge Graph. Under her leadership, January AI has built the industry’s most advanced lifestyle intelligence platform, integrating food, activity, sleep, and glucose insights. Time Magazine, CES, Fast Company, Inc., and The Wall Street Journal have recognized the company’s work, and Hashemi was named to Forbes’s 50 Over 50 list. She has spoken on leading stages, including CES, HLTH, and the Fortune Global Forum. Previously, she spent ten years at Oracle, helping scale revenues from $26 million to $3 billion. Today, she also serves on multiple advisory boards at Stanford, Tufts, and the Council on Foreign Relations.

• Artificial Intelligence
• Diagnostics Innovation
• Precision Medicine

Colin Hill is a trailblazer in applying causal AI to precision medicine. Aitia, the company he co-founded and leads, has built a powerful Digital Twin discovery and drug development platform, with a current focus on neurodegenerative diseases and oncology. He serves on the boards of Fulcrum Therapeutics (NASDAQ: FULC, a rare genetic disease company, Centrexion Therapeutics, a non-opioid pain therapeutics company, and the Critical Path Institute, which fosters collaborations between scientific and regulatory bodies.He previously served on the boards of mobile health company Biotelemetry Inc., CRO PPD Inc., and sickle cell disease company AesRx.In 2004, Colin was named to MIT Technology Reviews TR100 list of the top 100 innovators in the world under the age of 35. He has appeared in publications and television programs including The Wall Street Journal, CNBC Morning Call SquawkBox, Nature, Boston Globe, Politico, Forbes, Wired, and The Economist.

• Artificial Intelligence

Damon is head of Illumina’s Global Market Access. Prior, Damon held multiple leadership positions at Catholic Health Initiatives (CHI), culminating in leading the Precision Medicine Alliance of CHI and Dignity Health (the Precision Medicine Alliance of CommonSpirit Health). Before CHI, he was clinical business leader for Complete Genomics. Earlier, he led the Life Science segment of Strategic Diagnostics’ (SDIX, now Origene) antibody and assay business, including IVD production, research tools and therapeutic candidate generation. Earlier, Hostin managed GenVis Labs, a clinical molecular diagnostic company purchased by Pfizer in 2005. As a part of the founding Team of Actinium Pharmaceuticals, he managed alliances in developing targeted oncology therapeutics. His start in genomics was as Team Leader, Sequencing at Celera Genomics, where he was published on the Human and Drosophila genomes in Science and contributed to pharmaceutical partnerships. His education includes undergraduate studies at Tulane University, Masters studies at Harvard, and certificate programs at Wharton and the NIH.

• Diagnostics Innovation

Bill is a Venture Partner with Genoa Ventures. With more than 25 years of life science and technology experience, Bill is a respected expert in both basic research and clinical lab technology development. At the University of California San Francisco, Bill directed one of the largest academic core facilities in the world with a strong concentration on cytometry and genomic technologies implementing a myriad of research, translational and clinical applications. His academic career included joint appointments at UC Berkeley and the Lawrence Berkeley National Lab, three honorary doctorates, and authorship of over 100 peer-reviewed publications. Bill has been directly involved in the conception, design, engineering, and validation of numerous commercially successful analytical instruments, consumable products, and software programs, often in collaboration with companies like Carl Zeiss, Danaher, Thermo-Fisher, Becton Dickinson, and Sony Corp. Bill's career is characterized by his ability to repeatedly identify opportunities for disruptive science and technology in transformative markets and to add value through the life cycle of a start-up. Bill has been a founder, investor, and/or advisor to more than 50 companies including Mission Bio, CellFe, Immusoft, Precision Biologics, Cytobank, True Materials, Juno Bio, Accuri Cytometers, Intabio, Applaud Medical, Vitra Bio, Biotrue, QDot Corp, Zephyrus, Akadeum, and Fluent Bio with the common goal of impacting healthcare worldwide. Bill has served as Venture Partner with two Bay Area venture groups focused on early-stage investment and is closely affiliated with four life tech incubators. Bill joined Genoa to invest in unique health tech opportunities where there is a synergy of sound science coupled with sophisticated technology. Bill believes it takes a special blend of science nerd, business acumen, and knowing the commercial need to jump into this space.

• Diagnostics Innovation

Dr. Anshu Jain is Zephyr AI’s Chief Business and Clinical Officer. A double board-certified radiation oncologist and clinical informatician, he leads business development, clinical strategy, medical affairs, and partner collaborations-translating Zephyr’s AI and large-scale real-world data into solutions that help biopharma and diagnostic partners advance precision medicine for patients. Prior to Zephyr, Dr. Jain served as Chief Medical Officer at Aster Insights. Dr. Jain has authored peer-reviewed publications in Nature Communications, Journal of Clinical Oncology (JCO), and JCO Clinical Cancer Informatics, and has served as a principal investigator for early- and late-phase oncology trials. He has advised the FDA Office of the Commissioner and the Oncology Center of Excellence, and provided clinical leadership to large-scale data initiatives including the NCI SEER program. He serves on the Board of Directors of the Community Oncology Alliance, the Board of Advisors for the Duke Cancer Institute, and is an Assistant Professor at the Yale School of Medicine. Dr. Jain trained in internal medicine and radiation oncology at the Massachusetts General Hospital and Columbia New York Presbyterian Hospital. He earned his M.D. with Highest Distinction from the University of Kentucky College of Medicine and a degree in Economics from Duke University.

• Artificial Intelligence

Taylor Jensen, Ph.D. serves as Vice President, Head of Oncology Science at Labcorp where he leads research and development, bioinformatics, software development, and manufacturing for precision oncology laboratory offerings and products. After studying in the field of cancer epigenetics, Dr. Jensen joined Sequenom in 2009 and was a key contributor of the team that developed and launched the first commercially available, noninvasive, prenatal test based on circulating cell-free DNA (cfDNA) in the U.S. Subsequently, Dr. Jensen was involved in numerous assay development efforts focused on the identification and detection of genomic and epigenetic changes in cfDNA for use in prenatal and cancer diagnostics. Since the acquisition of Sequenom by Labcorp in 2016, Dr. Jensen has held several positions focused on driving the advancement of innovative oncology assays, including the development and validation of laboratory developed tests (LDTs) pursuant to CAP/CLIA and New York State requirements, and the development an in vitro diagnostic (IVD) test, the first FDA-authorized kitted liquid biopsy solution. In addition to these accomplishments, he had general management responsibilities for the companion diagnostic development organization, including oversight of the regulatory affairs team that led to the approval of Labcorp’s first CDx assay that is used to identify patients eligible for a gene therapy. Overall, Dr. Jensen’s work has primarily focused on pioneering novel technologies and assays with the overarching goal of utilizing these technologies to improve human health. He is a member of multiple professional societies including the American Association for Cancer Research and the American Society of Clinical Oncology, has contributed to multiple awarded patents, and has authored or co-authored more than 40 publications in peer reviewed scientific journals. He holds a Ph.D. in Pharmacology and Toxicology from the University of Arizona and was a postdoctoral fellow at the Arizona Cancer Center.

• Precision Medicine

Kyle Farh, MD, PhD, is VP & Distinguished Scientist has been at Illumina since 2015 and leads the Artificial Intelligence lab at Illumina. The AI lab has been responsible to a large extent for the adoption of deep learning in clinical variant interpretation, including the pioneering SpliceAI and PrimateAI-3D algorithms, two widely used AI tools for clinical interpretation of human genetic variants. He holds a BS in computer science from Rice University, and MD/PhD degrees from Harvard Medical School and the Massachusetts Institute of Technology in molecular biology. He completed his internship and residency in pediatrics and clinical genetics at Boston Children’s Hospital and his postdoctoral fellowship with Mark Daly and Brad Bernstein at the Broad Institute.

• Artificial Intelligence

Amirali Kia is Vice President of AI and Data Science at Element Biosciences, where he drives the application of AI across sequencing technologies, biological data analysis, and next-generation discovery platforms. With experience across genomics, diagnostics, and computational biology, his work bridges foundational AI research and large-scale life science applications. Amirali holds a PhD from Stanford University in high-performance computational biology.

• Artificial Intelligence

Dr. Mark Kiel is the founder and chief scientific officer at Genomenon, where he oversees the company's scientific direction and product development. After spending 15 years preparing for a life of academic research, Mark became convinced that revolutionary change in genomics was more likely to emerge from industry.

In 2014, he founded Genomenon, an AI-driven genomics company addressing the challenge of connecting pharma researchers with evidence in the literature to help diagnose and treat patients with rare genetic diseases and cancer.

• Artificial Intelligence

Minlee Kim is the CTO of Genolution Inc., leading R&D for advanced healthcare technologies from development through commercialization. Her work focuses on delivering innovative, automated tools for academia, biopharma, and diagnostics companies, supporting molecular diagnostics, companion diagnostics, and liquid biopsy applications. Her experience spans both clinical and industrial environments, including roles at Beth Israel Deaconess Medical Center and Samsung Bioepis. She received her Ph.D. in Molecular Biology from Yale University and a B.S. in Biology from Brandeis University.

• Precision Medicine

Dr. Li serves as the CEO of Breakthrough Genomics. She previously held multiple executive positions as the Lab Director at Illumina Clinical Lab and Associate Director at Children’s Hospital Los Angeles. A renowned, U.S. Board-certified Clinical Molecular Geneticist, Dr. Li is a leading pioneer in applying Artificial Intelligence to the fields of genetics and genomics. Throughout her career, Dr. Li has been a featured speaker at a number of high-profile international conferences including American Society of Human Genetics Conference, American College of Medical Genetics, Illumina Understand Your Genome symposium, The City of Hope Cancer Symposium, and is a published author in over a dozen peer-reviewed scientific publications including in the American Journal of Human Genetics, American Journal of Medical Genetics, Molecular Cell Biology, Journal of Next Generation Sequencing and Application, Genetic Medicine, and others. Dr. Li holds a Ph.D. from the Johns Hopkins School of Medicine and is board-certified by the American Board of Medical Genetics and Genomics. She serves on the ClinGen Gene-Disease Curation Expert Panel and led Breakthrough Genomics to become a major contributor to the ClinVar database. In 2018, she was honored as Woman of the Year by the San Diego International Association of Women. In 2024, Dr. Li received the Breakthrough Medical Technology in Diagnostics Award from the California Innovation Foundation.

• Diagnostics Innovation

C. Jimmy Lin, MD, PhD, MHS, is the the Chief Scientific Officer (CSO) at Freenome, working on early diagnosis of cancers. Previously, he was the CSO, Oncology at Natera (NASDAQ: NTRA), where he led the development of new diagnostic technologies for cancer. Dr. Lin is also a 2016 Senior TED Fellow and Founder & President of Rare Genomics Institute, the world's first platform to enable any community to leverage cutting-edge biotechnology to advance understanding of any rare disease. Previously, Dr. Lin led the ClinOmics program in the Genetics Branch of the National Cancer Institute (NIH/NCI). Prior to this, he led the computational analysis of the first ever exome sequencing studies of cancer at Johns Hopkins and was a research instructor at Washington University in St. Louis. He has numerous publications in Science, Nature, Cell, Nature Genetics, and Nature Biotechnology, and has been featured in Forbes, Bloomberg, Wall Street Journal, New York Times, Washington Post, BBC, TIME, and the Huffington Post.

• Artificial Intelligence
• Precision Medicine

Dr. Arturo Loaiza-Bonilla, MD, MSEd, is the Co-Founder and Chief Medical AI Officer at Massive Bio, a global industry leader in connecting patients to clinical trials using artificial intelligence. An internationally renowned medical oncologist and researcher, Dr. Bonilla has a distinguished academic and clinical career in precision medicine oncology, immunotherapy, clinical trial design, digital health, entrepreneurship, and patient advocacy. Dr. Loaiza-Bonilla is board certified in both medical oncology and hematology and has extensive experience in the diagnosis and treatment of genomic biomarker-driven cancers and serves as enterprise Chief of Hematology and Medical Oncology at St. Luke's University Health Network. Dr. Loaiza-Bonilla earned a medical degree from the Universidad Nacional de Colombia in Bogotá, Colombia. Following medical school, he completed an internship and residency in internal medicine at Harbor Hospital Center, Johns Hopkins Hospital in Baltimore, Maryland. Dr. Loaiza-Bonilla also completed a fellowship in hematology and oncology from the University of Miami, Miller School of Medicine in Miami, Florida. He completed his master’s degree in medical education at the University of Pennsylvania, and pursued professional certification in Artificial Intelligence in healthcare at the MIT Sloan School of Management. Before joining Capital Health, Dr. Loaiza-Bonilla was vice chairman of the Department of Medical Oncology at Cancer Treatment Centers of America in Philadelphia, Pennsylvania, as well as enterprise director of research, where he provided leadership and expertise to their oncology trial portfolio across 5 cancer centers and over 70 NCTN and industry-sponsored clinical trials. His research has been extensively published in the most prominent journals and meetings in oncology, and he has been recipient of NIH funding to advance digital health and artificial intelligence tools for cancer research. He was also assistant professor of Clinical Medicine at the University of Pennsylvania School of Medicine; and he is currently assistant professor in the Department of Medicine at Drexel University College of Medicine, both in Philadelphia. Throughout his stellar career, Dr. Loaiza-Bonilla has held numerous leadership positions such as President of the Pennsylvania Society of Oncology and Hematology and President of the Board of Directors of the Global Alliance for Patient Access. In 2018, he was recognized as Philadelphia Business Journal’s Forty Under 40, in 2019 he was bestowed the Influencers of Healthcare Award - Outstanding Healthcare Provider award by the Philadelphia Inquirer, and in 2021 he was chosen as recipient of '40 under 40 in Cancer' accolade. He has also been selected in Castle Connolly's and Philadelphia Magazine's Top Doctors listing since 2018.

• Artificial Intelligence

Dr. Beth Marlowe is the Executive Scientific Director and heads R&D for Quest Diagnostics Infectious Diseases and immunology. Dr Marlowe joined Quest in June of 2019. Beginning January of 2020, her team played a key role in the COVID-19 response and in 2022, the Mpox response. Previously she has worked as the Global Director of Medical Affairs for Microbiology at Roche Molecular Systems, provided laboratory leadership for over a decade within the Kaiser Permanente Regional Laboratories, and assay development for Gen-Probe (now Hologic). She is a diplomat of the American Board of Medical Microbiology, past-president for the SoCal branch of the American Society for Microbiology (ASM), served as an editor for the Clinical Microbiology Newsletter as well as the Journal of Clinical Virology. She has served as an elected member to the Council on Microbial Sciences for ASM, an appointed member of CLIAC, the federal advisory committee for CLIA to the United States HHS Secretary, and an elected member of the Board of Directors for ASM. Her research areas of interest are focused on the translation of new infectious disease diagnostics for use in evidence-based research for clinical and public health microbiology practice.

• Diagnostics Innovation

Jean-Francois Martini has biopharma and diagnostics industry experience in pharmacology and clinical translational sciences and is author/coauthor of over 60 scientific publications. He is currently Senior Director, Translational Strategy and Applications at Guardant Health, joining a year ago after more than 13 years at Pfizer where he was Executive Director, Biomarker Clinical Assay and Technology Group Head in the Translational Science Operation organization within the Pfizer Oncology Division. While at Pfizer, he led and/or supported the diagnostics and translational strategies for the cell cycle modulators (CDK inhibitors); the Renal Cell Cancer franchise (sunitinib, axitinib); the Lung Cancer franchise (lorlatinib; encorafenib+binimetinib; etc); and Colorectal cancer; and was involved in the diagnostics development for the gene therapy portfolio, and the approval of BEQVEZ (Fidavec) for the treatment of hemophilia B. He also led the cross-functional efforts in the area of liquid biopsy/cfDNA (represents Pfizer as part of Blood Profiling Atlas-Cancer; Friends of Cancer Research) and was the Pfizer board of director representative for the WIN consortium. He was based at the Pfizer-La Jolla site, California, for 13+ years. Before joining Pfizer, he was Sr. Director, Translational Medicine, at Exelixis, So San Francisco, California, where he contributed to the approval of cobimetinib and cabozantinib, and to projects such as the alliance with Sanofi for the PI3K programs and out-licensing of esaxerenone (MR inhibitor approved for hypertension) to Daiichi Sankyo. He completed his postdoctoral training at University of California, San Francisco, where he studied the antiangiogenic properties of fragments of Prolactin and Growth Hormone, after obtaining a PhD in Biochemistry (Molecular and Cellular Endocrinology) from University Paris XI, and a MSc. in Neuroscience (Neuroendocrinology) from University Paris VI, France.

• Precision Medicine

Dr. Ian McCaffery is Vice President and Global Head of Precision Medicine, Translational Research & Companion Diagnostics at AbbVie, where he leads precision medicine strategy across all therapeutic areas from discovery through post-launch. The team is integrating AI/ML into precision medicine using real-world data, multi-modal analyses, and digital pathology to inform patient selection, accelerated approvals, disease strategies, and indication expansions, as well as leveraging clinical data to develop new therapeutic programs and combinations. Prior to AbbVie, Dr. McCaffery held leadership roles at Johnson & Johnson Innovative Medicine, Genentech, and Amgen, with extensive expertise in biomarker development, companion diagnostic development and approvals, and real-world data partnerships. He holds a Ph.D. in Biochemistry and Molecular Biology from the University of Leeds and completed postdoctoral training at the University of Virginia. Dr. McCaffery serves on multiple industry consortia steering committees focused on advancing precision medicine and regulatory innovation.

• Precision Medicine

Michael Mina, MD, PhD is an epidemiologist, immunologist and clinical pathologist. He is also an executive and consultant to governments, biotech, and life sciences companies. He was formerly a professor in the Departments of Epidemiology and Immunology & Infectious Diseases, at the Harvard T.H. Chan School of Public Health; in clinical pathology at Harvard Medical School and an associate faculty at the Broad Institute of MIT and Harvard. He was the associate medical director for molecular virology diagnostics at Brigham and Women's Hospital and started and helped lead the Broad Institute’s high throughput COVID-19 testing facility. His research focused on developing extremely multiplexed assays for immune profiling and mathematical models towards understanding effects of viral infections on immunity; the development and maintenance of immunity through life; and development of a global immunological observatory for pathogen spread. Dr. Mina became Chief Science Officer of eMed, a digital first healthcare company that improves effectiveness of home-based testing by linking home tests to telemedicine. In 2020, eMed collaborated with Abbott to bring the first low-cost COVID-19 rapid test - the BinaxNOW Home Test - into US Households enabling real-time result certification and public health reporting from anywhere helping millions of people travel internationally and return to work and school. Dr. Mina is also the Executive Director of the Immune Observatory, a 501(c)3 not-for-profit for pathogen monitoring and surveillance through next generation immunological tools. Dr. Mina advises US Federal and state governments, including both White Houses through COVID-19, US Congress, CDC, and FDA. He was the recipient of the NIH Director's Early Independence Award and was named by the Economist as a Global Progress Maker. He currently helps lead numerous large NIH funded programs including leading the implementation of the NIH Home Test to Treat Program and co-PI of the COVID-19 Paxlovid Rebound Cohort Study

• Diagnostics Innovation

No bio available.

• Diagnostics Innovation

After completing my MD/PhD (Immunology) training at Mayo Medical School in 1994 I completed an intern year and AP/CP residency, and surgical pathology and hematopathology fellowships at the Mayo Clinic College of Medicine and joined the staff as a hematopathologist in 2000. I served as the division chair of hematopathology at Mayo Clinic from 2009 to 20015, as the Chair of the Mayo Clinic Department of Laboratory Medicine and Pathology, and President of Mayo Clinic Laboratories from February 2015 until November 2022, and now serves as the President & CEO of Mayo Collaborative Services/Mayo Clinic Laboratories. I have been blessed to have a rewarding career as an academic pathologist developing new clinical laboratory tests for the diagnosis of hematologic malignancies and authoring over 200 papers, abstracts, and book chapters. I have carried my passion for innovation into my leadership roles working to conceptualize and lead implementation of ideas that expand delivery of diagnostic services globally and continue to establish, manage, and maintain Mayo’s reputation as prestigious, world-renowned global reference laboratory assisting healthcare providers worldwide advance patient care and broaden access to specialized testing. In addition to my leadership roles at Mayo Clinic, I have served as the Chair of the Board of Directors of the American Clinical Laboratory Association and the Co-Chair of the Industry Advisory Group to the Global Fund Access to Covid Tools Accelerator-Diagnostics.

• Artificial Intelligence
• Diagnostics Innovation
• Precision Medicine

Andy Moye is currently the Senior Vice President and General Manager of Real-world Data for Tempus AI, a company dedicated to improving patient outcomes through AI and data. He was previously Chief Executive Officer and board member for Paige, a spinout company from Memorial Sloan Kettering Cancer Center in New York City. Andy has always been driven to serve others, and began his career as a Flight Officer in the US Navy, flying missions in Iraq and the Middle East from 1998 through 2006. Dr. Moye is also passionate about making a difference in the fight against cancer, and has worked across the molecular diagnostics, biotechnology, Real World Data (RWD), and life sciences industries at the forefront of precision medicine in oncology. Notably, he served as Head of Commercial Operations in North America and Latin America for Philips Digital Pathology solutions, and in senior executive roles at leading healthcare companies including Ontada, a division of McKesson, Caris Life Sciences, and WaferGen Bio-systems, now part of Takara Bio. Andy Moye’s educational career includes a Bachelor of Science in Physiology from the University of Arizona, an MBA from the University of Florida, and a PhD in Health Economics from Walden University.

• Precision Medicine

Susanne Munksted, Chief Precision Medicine Officer of Diaceutics, brings a wealth of experience to her role in leading a global team of precision medicine industry experts dedicated to enhancing the testing ecosystem to help patients capitalize on new breakthrough personalized medications. Susanne's journey in molecular pathology has been marked by notable achievements, including spearheading several global launches of companion diagnostic products. As a leading author of the Practice Gaps Study, Susanne played a pivotal role in identifying seven key clinical practice gaps contributing to patient leakage, and her impactful contributions to the field have earned her a well-deserved place among the PharmaVoice 100 list of transformational leaders in life sciences.

• Precision Medicine

Brad is Delve Bio’s CEO and co-founder. Most recently, Brad was a senior associate at Xontogeny, where he made seed and series A investments across the life sciences. Previously, Brad was a computational biologist at Intellia Therapeutics applying his expertise to CRISPR/CAS9 therapeutics. Prior to Intellia, Brad was a computational associate at The Broad Institute where he developed algorithms for the analysis of cancer genome sequencing data. Brad holds a BS in Biology and Economics from Georgetown University and an MBA in finance and entrepreneurship from Boston College.

• Diagnostics Innovation

No bio available.

• Precision Medicine

Jonathan is CEO and co-founder of QuantuMDx Group, a UK-based life sciences company who have developed a multiplex point-of-care molecular diagnostics device & a device for cellular concentration and rapid AST. He is the co-inventor of QuantuMDx’s proprietary Q-POC & Capture-XT devices and disposables. Jonathan is dedicated to tackling global issues such as M.tuberculosis, antimicrobial resistance and was a diagnostics advisor for the UK Governments O’Neill Review on AMR. He was also part of several UK government-led COVID-19 diagnostic committees, including the Manufacturing Industry Coalition Working Group and the Molecular PoC Working Group. Jonathan was awarded European CTO of the Year in 2015 and is an active angel investor and board member of many exciting life science tools and diagnostics companies in the UK.

• Diagnostics Innovation

Jai Pandey currently serves as Director of Global Regulatory Strategy IVD at Bayer. Prior to joining Bayer, he worked as a Regulatory Lead at GSK for strategic and innovative precision medicine and digital health approaches. From 2017-2020, Jai was a lead IVD device reviewer at FDA/CDRH. Jai did his postdoctoral training at the Whitehead Institute of MIT. He holds a PhD in Cellular and Molecular Biology from University of South Carolina.

• Precision Medicine

Nakiya Parkes is a Director of Health Policy & Market Access with over 12 years of experience driving payer engagement, reimbursement strategy, and access expansion across diagnostics, medical devices, and pharmaceuticals. Known for her ability to translate complex clinical and economic evidence into actionable coverage outcomes, she has led high-impact initiatives that secured favorable policies with national and regional payers-including Cigna, Aetna, Blue Cross Blue Shield, and multiple Medicaid programs-resulting in expanded access for over 60 million covered lives. Currently at bioMérieux, Nakiya oversees payer strategy across national, regional, and government stakeholders. Her collaborative approach bridges policy development, payer engagement, and cross-functional alignment, making her a trusted partner to internal teams and external decision-makers alike. She holds a Master of Public Health in Health Policy & Management and an MBA in Healthcare Administration. Nakiya serves on AdvaMed’s Payer and Policy Advocacy Committee and the Reimbursement Working Group, and is a member of the Infectious Disease Society of America (IDSA). Her work is grounded in a passion for health equity, system-level change, and ensuring innovative diagnostics reach the patients who need them most.

• Diagnostics Innovation

Daryl Pritchard, PhD, is the Senior Vice President of Science Policy at the Personalized Medicine Coalition (PMC), where he leads PMC’s efforts to increase awareness and understanding of personalized medicine; identify and address barriers to the adoption of personalized medicine into the health care system; and develop and promote appropriate clinical, health care infrastructure, regulatory, and payment policies. Before coming to PMC, Dr. Pritchard served as the Director of Policy Research at the National Pharmaceutical Council (NPC). Prior to joining NPC, he served as the Director of Research Programs Advocacy and Personalized Medicine at the Biotechnology Industry Organization (BIO). Dr. Pritchard received his PhD and master’s degree in genetics from the George Washington University, and completed a post-doctoral research fellowship at the Children’s National Medical Center. He was awarded the first American Society of Human Genetics (ASHG)/National Human Genome Research Institute (NHGRI) Fellowship in Genetics and Public Policy, where he worked as a health legislative assistant in the House of Representatives.

• Precision Medicine

COMPANY STATEMENT Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. SAM RAHA - PRESIDENT AND CEO, MYRIAD GENETICS Sam Raha has been Myriad Genetics’ President and CEO since April 2025. He joined Myriad as COO in December 2023, with a focus on driving increased patient access and profitable growth by strengthening innovation, operational execution and the patient and provider experience. Previously, Sam was the President of Agilent Technologies’ Diagnostic and Genomics Group with responsibility for its strategy, innovation and results. Prior to Agilent, he led Marketing and Product at Illumina and before that was the VP and General Manager of the TaqMan/qPCR business at Life Technologies. Sam earned his MBA from Santa Clara University and has an undergraduate degree in molecular and cell biology from the University of California, Berkeley.

• Precision Medicine

No bio available.

• Artificial Intelligence

Visionary AI Executive and Bestselling Author of Applied Machine Learning for Healthcare and Life Sciences Using AWS. Over 20 years of experience at the intersection of AI, Cloud Computing and Healthcare & Life Sciences. Proven track record of defining and executing AI driven Enterprise-wide transformations for Global Fortune 500 organizations. Recognized industry thought leader who has shaped national policy through engagements with the White House Office of Science & Technology Policy and the FDA. Expert in transforming complex clinical, imaging and genomic data into scalable, revenue-generating products in the Amazon Health AI category. Skilled in bridging the gap between technical engineering teams and C-suite business goals, driving innovation in Generative AI, Precision Medicine, and Regulatory Compliance.

• Artificial Intelligence
• Diagnostics Innovation
• Precision Medicine

Genoa Ventures’ founder and managing director Jenny Rooke deploys capital at the frontiers of life sciences innovation, with a focus on technology-fueled solutions and category-defying opportunities. Her background includes a PhD in genetics from Yale, management consulting experience to pharma and biotech leaders at McKinsey, and operating experience in a genomics start-up. Jenny got her start in venture at Fidelity Biosciences (now F-Prime Capital), and then brought her toolkit of genetics expertise, business strategy, and venture investing to the Gates Foundation, where she managed over $250M in funding in genetic engineering, diagnostics, and synthetic biology. Jenny founded San Francisco-based Genoa Ventures to be the investing partner of choice for early-stage companies innovating at the convergence of biology and technology.

• Artificial Intelligence
• Diagnostics Innovation
• Precision Medicine

Rafael Rosengarten is CEO and co-founder of Genialis, the AI algorithms company transforming the way we diagnose and treat cancer. He envisions a world in which healthcare delivers the best possible outcomes for patients, their families and communities. Before leading Genialis’ effort to realize the promise of precision medicine, he spent nearly 20 years in biomedical research, publishing in the fields of evolution, immunology, bioengineering and genetics. Dr. Rosengarten is also a board member and co-founder of the Alliance for AI in Healthcare (AAIH), a non-profit global advocacy organization. Rafael attended Dartmouth College before earning his doctorate from Yale University, where he was an NSF Graduate Research Fellow. He went on to postdoctoral training in Jay Keasling’s synthetic biology group at Lawrence Berkeley National Laboratory, Joint BioEnergy Institute (JBEI), where he caught the entrepreneurship bug. This was followed by a National Library of Medicine fellowship in Biomedical Informatics at Baylor College of Medicine, where he fell in love with machine learning. In his free time, Rafael enjoys cooking, climbing mountains and exploring the world with his wife and two precocious children.

• Artificial Intelligence

Mike Ryan advises clients on the legal, regulatory, and reimbursement issues that arise during the development and commercialization of medical devices, clinical laboratory testing services, biological products, and drugs. He guides clients by evaluating and implementing strategies to optimize coding, coverage, and payment for novel technologies. Michael also helps innovative companies identify and navigate applicable FDA regulatory requirements for new technologies, particularly in vitro diagnostics and digital health products.

• Diagnostics Innovation

Cecilia Schott is the Head Global Precision Diagnostics - Oncology Translational Medicine at GSK. She joined GSK early 2024 from Novartis where she led the Global Commercial Precision Medicine group delivering comprehensive cross-functional and cross oncology brand diagnostic strategies through the entire product life cycle. Prior to Novartis, she was responsible for establishing a portfolio of partnership agreements and products with diagnostic companies enabling access to a range of technologies delivered through global drug launches at AstraZeneca. Cecilia’s background includes roles in Global Marketing, Medical Affairs and Clinical Trial Operations. Cecilia was part of Biogen’s Drug Safety and Medical Information function, and at Boston Scientific she was responsible for establishing the drug eluting stent franchise Medical Publication and Medical Information groups within Medical Affairs. Cecilia holds a BS in Pharmacy from the University of Sao Paulo, Brazil; a Doctor of Pharmacy from Massachusetts College of Pharmacy, Boston and a MBA from Babson College, Boston.

• Precision Medicine

Brock Schroeder, PhD is Vice President of Worldwide Market Access Strategy and Americas Market Access at Cepheid where he leads efforts focused on developing Market Access strategies to drive medical and public policy for Cepheid’s clinical applications in Infectious Diseases, Women’s and Sexual Health, Virology, Health-related Acquired Infections and Oncology globally, and is responsible for driving engagements with payers, the commercial organization and our Lab customers in the Americas. Prior to Cepheid, Brock was Vice President of Market Access at Illumina, where he led efforts to demonstrate the compelling value of next-generation sequencing (NGS)-based clinical applications to payers and health technology assessment (HTA) agencies globally supported by robust clinical and economic evidence to maximize and accelerate patient access and improve health outcomes. Prior to Illumina, Brock led Medical & Scientific Affairs at Biotheranostics (since acquired by Hologic), where his team focused on generating and communicating evidence supporting the clinical and economic utility of 2 proprietary molecular diagnostic assays in the oncology therapeutic area--leading to US Medicare coverage for both assays. Brock's industry experience includes multiple therapeutic areas including oncology, rare disease, reproductive health, infectious diseases, and metabolic disorders. Brock has authored >30 peer-reviewed manuscripts, >60 scientific congress abstracts, and multiple book chapters. He received his BA in Biology from Washington University and his PhD in Neuroscience from the University of Wisconsin-Madison.

• Diagnostics Innovation

Premal Shah, PhD, is the CEO of MyOme, a genomics innovation company focused on preventive health and rare disease diagnostics. With over 20 years of experience in biotech and healthcare, he is dedicated to advancing precision medicine and genomics-driven health solutions. Previously, Premal was Co-Founder & President at Ciitizen, a digital health company empowering patients with their own health data, where he oversaw operations and strategic development, including go-to-market strategies. Before Ciitizen (acquired by Invitae), he served as CEO of Applied Proteomics, a company pioneering a blood-based colorectal cancer diagnostic test. Prior to that, he led corporate development at Genomic Health (now part of Exact Sciences). He holds a PhD in computational biology from the California Institute of Technology, with several publications in the field.

• Artificial Intelligence

Mr. Sheives is the Vice President of Government Affairs with Myriad Genetics, and is based out of their Government Affairs office in Washington, DC. In this role, Mr. Sheives leads the Company’s Federal and State Government Affairs activities to ensure access to the company’s advanced diagnostic services. He is a leader in public policy development in the clinical laboratory space and has a deep understanding of legislative strategy and health care reimbursement policies. With a background in molecular biology, regulatory law, and reimbursement counseling, Mr. Sheives has represented companies throughout the spectrum of biotechnology. Prior to joining Myriad Genetics, Mr. Sheives served as Vice President, Government Affairs at DELFI Diagnostics, Sr. Director, Reimbursement & Health Policy at Roche Diagnostics, Vice President, Reimbursement & Regulatory Affairs at the American Clinical Laboratory Association, and was Director for Personalized Medicine & Diagnostic Policy at the Biotechnology Industry Organization (BIO). Before BIO, Mr. Sheives practiced in two large, international law firms as a legal associate and regulatory science advisor in the areas of FDA and reimbursement law. He holds a J.D. from the Georgetown University Law Center, a M.S. in Molecular and Cellular Biology from the University of Texas Southwestern Medical Center at Dallas, and a B.S. in Microbiology from the University of Texas at Arlington.

• Diagnostics Innovation

Dr. Joe Shonkwiler is currently leading the Healthcare and Life Science (HCLS) practice for startups and investors at Google Cloud. Dr. Shonkwiler joined Google from the Advanced Research Projects Agency for Health (ARPA-H), a federal agency established by the Biden administration to invest in breakthrough technologies and transform medicine. He served as ARPA-H's founding Chief Operating Officer (COO) and Acting Deputy Director. In those roles he led all the business and administrative operations for the agency, including commercialization, finance, AI and data infrastructure, IT, contracting and acquisitions, and human resources. Since founding in 2023, ARPA-H has deployed over $3B in nondilutive funds to transform health and biomedical R&D. Prior to ARPA-H, Dr. Shonkwiler was part of the HCLS startup BD team at Amazon Web Services (AWS). In that role, he advised hundreds of healthcare and life science startups, guiding them from conception to exit. He also founded and hosted the AWS Health Innovation Podcast, a weekly show featuring entrepreneurs and investors driving progress in healthcare and life science globally. Prior to joining Amazon, Dr. Shonkwiler was an early employee and VP at Aledade, a venture-backed startup helping independent primary care practices succeed in value-based care. In that role, he drove national implementation of Aledade's software and services, expanding coverage across 40 states and 500 practices to serve over 500,000 Medicare beneficiaries. Before Aledade, he was the CEO of CollectedMed, a cloud-based health education software startup spun out of Columbia University’s Department of Surgery. Dr. Shonkwiler served on Capitol Hill as the Senior Health Policy Advisor for former United States Senator Rob Portman, handling all federal health policy matters. He began his career as a general surgery resident at Columbia University Medical Center/New York Presbyterian Hospital. Dr. Shonkwiler has a BA from the University of Notre Dame, an MD from Columbia University, an MBA from MIT’s Sloan School of Management, and an MPP from Princeton University.

• Artificial Intelligence
• Diagnostics Innovation
• Precision Medicine

Ajit is CEO of Harbinger Health. He was previously Managing Director at Silicon Valley based Artiman Ventures. He is also an Adjunct Professor in the School of Medicine at Stanford and serves on the Board of Trustees of American Association for Cancer Research (AACR) Foundation. Additionally, he is on the Board of Directors of Onconetix, Leo Cancer Care, Artidis, and Sofie Biosciences. In the past, he has served as the global CEO of Siemens Oncology. Subsequently, he was the CEO of BioImagene, a cancer diagnostics startup, acquired by Roche. He also served as Senior Advisor to the Tata Trusts Cancer program. Ajit has a PhD in Computer Science from Columbia, a Master’s in Computer Engineering from Syracuse and a bachelor’s in Electrical Engineering from Banaras Hindu University. He has published 2 books and 5 patents. His Top-10 Book Review is carried by various blogs and journals in December every year.

• Artificial Intelligence
• Diagnostics Innovation
• Precision Medicine

Marina is currently an Associate Professor at the Bakar Computational Health Sciences Institute at UCSF. Prior to that she has worked as a Senior Research Scientist at Pfizer where she focused on developing Precision Medicine strategies in drug discovery. She completed her PhD in Biomedical Informatics at Stanford University. Dr. Sirota’s research experience in translational bioinformatics spans over 10 years during which she has co-authored over 80 scientific publications. Her research interests lie in developing computational integrative methods and applying these approaches in the context of disease diagnostics and therapeutics with a special focus on studying the role of the immune system in disease. The Sirota laboratory is funded by NIA, NLM, NIAMS, Pfizer, March of Dimes and the Burroughs Wellcome Fund. As a young leader in the field, she has been awarded the AMIA Young Investigator Award in 2017. Dr. Sirota also is the director of the AI4ALL program at UCSF, with the goal of introducing high school girls to applications of AI and machine learning in biomedicine.

• Precision Medicine

As a pioneer of Precision Medicine, Dr. Michael Snyder has invented many technologies enabling the 21st century of healthcare including systems biology, RNA sequencing, and protein chip. Dr. Snyder has initiated the Big Data approach to healthcare through his work using omics to detect early stage disease, including wearables to detect infectious diseases like COVID-19, and at-home microsampling to measure hundreds of molecules from a single drop of blood. He is the first researcher to gather petabytes of data on individuals, which is 1 Million - 1 trillion times more data than the average clinician collects. He as published over 800 papers and is one of the most cited scientists. In terms of commercial success, Mike has co-founded 17 companies (including 2 unicorns) with combined enterprise value of over $6 billion.

• Precision Medicine

Amy serves as EVP, Chief Marketing Officer and Consumer Business Lead at Labcorp. As a member off Labcorp’s Executive Committee, she is responsible for global marketing including brand and reputation, digital experiences and ecommerce, commercialization, product management, insights, and communications. Amy also leads the company’s Consumer businesses under the brands Labcorp OnDemand and Ovia Health which offer health and wellness solutions to consumers, including at-home testing, mobile apps focused on women's health and pregnancy, health coaching and access to Labcorp's array of testing. She is a member of Labcorp’s ESG and Venture Fund Steering Committees and serves as the Executive Sponsor for EnABLE (resource group for people with disabilities). Prior to Labcorp, Amy held executive leadership positions in marketing, sales and consulting at Ernst & Young, TE Connectivity, and digital consultancy Sapient. Amy is a Board Observer of venture-backed NowDX, and is a Board Director of the nonprofit No More Kids with Cancer. She also serves as a member of the Corporate Council of the Children’s Hospital of Philadelphia. Amy has received wide recognition for her leadership, including being named to the Forbes CMO Next list and being awarded the Customer Obsession award by Forrester Research. She holds a B.B.A. in Finance from Kent State University and an MBA in Finance and International Business from the Stern School of Business at New York University.

• Diagnostics Innovation

Tim Sweeney, MD, PhD, is co-founder and CEO of Inflammatix. Tim has extensive experience in medical practice (general & trauma surgery), bench research, and bioinformatics/machine learning. While training at Stanford he helped invent the core technology on which Inflammatix is based, is named on over a dozen patents related to medical diagnostics, and has published >100 manuscripts & abstracts. He is PI (through Inflammatix) on multiple development contracts from DARPA, BARDA, and NIH, and brought Inflammatix to recognition as the ‘Most Disruptive Technology’ at AACC in 2019, and the “Fierce 15” list in 2020.

• Diagnostics Innovation

Ephraim Tsalik is the VP and Chief Scientific Officer for Infectious Disease and Acute Care at Danaher Diagnostics. He obtained his MD and PhD from Columbia University. He then completed clinical training in Internal Medicine and Infectious Diseases at Duke University while earning a Master of Health Science in Clinical Research. Dr. Tsalik joined the Duke University faculty, rising to tenured associate professor, where his research focused on host response biomarkers for infectious disease. During his time at Danaher, Dr. Tsalik also served as the interim Chief Medical Officer at Cepheid. He remains clinically active at the Durham VA Health Care System and maintains an adjunct appointment with Duke University.

• Diagnostics Innovation

Dr. Mickey Urdea is Founder and Partner for Halteres Associates, a biotechnology consulting firm. He also founded and served as Chief Executive Officer of Tethys Bioscience, a proteomics-based diagnostics company that has been involved in the prevention of type-2 diabetes (acquired by HDL), and was Chief Executive Officer of Quantum Dots Corporation (acquired by Life Technologies). Additionally, Dr. Urdea is a founder and the Chairman of Catalysis Foundation for Health (CFH), a non-profit organization addressing gaps in global healthcare caused by inefficiencies in disease diagnosis and monitoring. Dr. Urdea was a member of the University of California at San Francisco Leadership Council for the Institute of Global Health. He serves as a consultant to the life sciences industry and is on the scientific advisory boards and boards of directors of a number of biotechnology and diagnostics companies. Prior to his current activities, Dr. Urdea founded the Nucleic Acid Diagnostics business at Chiron Corporation, where he pioneered viral load assays for the human hepatitis B, hepatitis C and immunodeficiency viruses; his team introduced the first commercial viral load assays for all three viruses. Dr. Urdea also headed the Oncology Diagnostics business unit at Chiron. He then became Senior Vice President of the Molecular Diagnostics group and Chief Scientific Officer at Bayer Diagnostics. He served as an advisor to the Bill & Melinda Gates Foundation for more than 15 years. Dr. Urdea is an author on over 200 peer-reviewed scientific publications and has more than 125 issued and pending patents. He received his BS in Biology and Chemistry from Northern Arizona University (NAU; Flagstaff, Arizona), his PhD in Biochemistry from Washington State University (Pullman, Washington) and had an NIH postdoctoral fellowship at the University of California (San Francisco, California). Dr Urdea received an honorary PhD degree rom NAU in 2022.

• Diagnostics Innovation

Megann Vaughn Watters is an experienced corporate development executive and investor with over a dozen years of novel technology identification, partnership development, deal execution, alliance management, financial and strategic return, and venture-backed board experience within the healthcare industry. As the Vice President of New Ventures & Strategic Alliances and Managing Partner of Labcorp Venture Fund, Megann manages the venture fund and leads the Corporate Development team tasked to identify, assess, and bring innovative science and technology to Labcorp through partnerships, such as equity investments, licensing, commercial collaborations, including data use agreements and sponsored testing programs with pharma. As one of the founding members of the Labcorp Venture Fund, Megann has managed more than $300M in total equity investments in over 80 early-stage private companies with novel science and technology making healthcare more convenient, accessible, data-driven and personalized. Megann previously held positions at the United States Patent and Trademark Office as a Patent Examiner for medical devices and Humacyte conducting tissue engineering research. Megann received her M.B.A. from the Duke University Fuqua School of Business and her B.S.E. in Biomedical Engineering from Duke University Pratt School of Engineering. Megann is a mother of two young kids, wife, daughter, sister, reader, yogi and Peloton enthusiast.

• Artificial Intelligence
• Diagnostics Innovation
• Precision Medicine

Catia is a Managing Director in L.E.K. Consulting’s Life Sciences practice, specializing in precision medicine, diagnostics, and advanced research tools. Since joining in 2017, she has advised biopharma, diagnostics, and research tools clients on growth strategy, commercial planning, and business development. Her project work includes designing diagnostic strategies for Alzheimer’s disease, advancing computational pathology and liquid biopsy applications in oncology, and crafting commercial strategies for novel diagnostic platforms. Prior to joining L.E.K., Catia was a Postdoctoral Fellow at the Wyss Institute at Harvard University, where her research focused on developing novel immunotherapies. She holds a Ph.D. in Bioengineering from Harvard University and a B.S. in Biology from the Massachusetts Institute of Technology.

• Precision Medicine

No bio available.

• Artificial Intelligence

No bio available.

• Diagnostics Innovation

Charity R. Williams brings a wealth of business acumen to her legal practice, specializing in representing both public and privately held life sciences companies in complex licensing and corporate partnering transactions. With a focus on strategic collaborations, license agreements, territory-specific licenses, and co-development, co-promotion and profit-sharing relationships, Charity offers a unique blend of legal expertise and business insight and is recognized for her comprehensive advisory role. Her expertise extends to handling options to purchase and earn-out structures in the context of mergers and acquisition and she also offers guidance on day-to-day matters encompassing licensing, supply, distribution, clinical trials, and vendor services. Having served as a dedicated member of the board of directors of Athena for six years, concluding her term in December 2023, Charity is deeply committed to leadership development for women in the life sciences, healthcare, defense, technology, and related business communities. Her contributions have been recognized through prestigious accolades such as the San Diego Business Journal’s Women Who Mean Business and Leaders in Law. Prior to rejoining Cooley, Charity navigated the entrepreneurial path, running her own practice where she successfully represented life science and technology companies in corporate and intellectual property litigation matters. Her extensive experience also includes serving as the chief business officer and in-house counsel for Catheter Connections, a medical device developer based in Salt Lake City, Utah. Notably, Charity's diverse background extends to leadership positions in the medical device industry, having served as the interim CEO of Veritract, a startup medical device company, and the director of marketing for ZEVEX (Moog Medical Devices Group). She also made significant contributions as a senior associate at the University Venture Fund, executing life science venture capital and growth equity investments. She also led her team to victory, securing the Life Sciences Grand Prize at the Carnegie Mellon McGinnis Venture Competition while serving as an associate at the Lassonde New Venture Development Center. Recognized for her achievements, Charity is a recipient of an In-Awe Award from the Medical Marketing Association. During her academic journey at the University of Utah S.J. Quinney College of Law, she earned prestigious distinctions, including election to the Order of the Coif and membership in the Utah Law Review.

• Artificial Intelligence
• Diagnostics Innovation
• Precision Medicine

Dr. Mike Zack is a physician-scientist and entrepreneur recognized as a leading expert in artificial intelligence, multi-omics, and precision medicine. For more than a decade, he has focused on developing technologies that integrate genetics, clinical data, and multilayer biomarkers to create practical tools for clinical decision-making. He is the Founder and CEO of PGxAI, an innovative platform that leverages agentic AI architectures and multi-omic data to improve treatment selection and therapeutic safety. Under his leadership, the company has developed advanced models capable of integrating genomic, transcriptomic, proteomic, metabolomic, and clinical features to generate transparent and reproducible recommendations. Dr. Zack’s scientific contributions include over 200 peer-reviewed publications, more than 70,000 citations, and an H-index of 53, placing him in the top 1 percent of most-cited researchers worldwide according to Elsevier. His work has significantly influenced pharmacogenomics and personalized therapy and has been implemented in medical centers across the United States, Europe, and the Gulf region. He collaborates closely with global technology and healthcare organizations, including Google, InterSystems, Amazon, and Microsoft, and plays a key role in advancing cutting-edge AI technologies and international frameworks for the safe, transparent, and reproducible integration of multi-omics into clinical practice.

• Artificial Intelligence

Dr. Zhongming Zhao holds University Chair Professor for Precision Health and is the founding director of the Center for Precision Health, and the director of CPRIT Cancer Genomics Core, the University of Texas Health Science Center at Houston (UTHealth). Before he joined UTHealth in 2016, he was Ingram Endowed Professor of Cancer Research, Professor of Biomedical Informatics at Vanderbilt University Medical Center, Chief Bioinformatics Officer of the Vanderbilt-Ingram Cancer Center (VICC), and Director of the VICC Bioinformatics Resource Center. Dr. Zhao has unique, interdisciplinary training: he received his master’s degrees in Genetics (1996), Biomathematics (1998), Computer Science (2002), Ph.D. degree in Human and Molecular Genetics (2000), and Postdoctoral Fellow in Bioinformatics (2001-2003). Dr. Zhao has broad interest in bioinformatics, genomics, precision medicine, and machine learning and has authored/co-authored >350 papers in these areas (H-index = 59). He has served as the PI of more than 30 grants and his research has been supported by more than $100 million. Dr. Zhao is the founding president of The International Association for Intelligent Biology and Medicine (IAIBM).

• Artificial Intelligence
• Precision Medicine